Merger uncertainty and impending trials for Bristol-Myers leave investors in limbo
June 05, 2019 at 12:09 PM EDT
Investors are taking a wait-and-see approach to Bristol-Myers Squibb Co., according to Credit Suisse.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|